晚期肝细胞癌全身治疗的进展
Evolution of systemic therapy of advanced hepatocellular carcinoma.
作者信息
Yau Thomas, Chan Pierre, Epstein Richard, Poon Ronnie-T
出版信息
World J Gastroenterol. 2008 Nov 14;14(42):6437-41. doi: 10.3748/wjg.14.6437.
Abstract
Hepatocellular carcinoma (HCC) commonly occurs in hepatitis B endemic areas, especially in Asian countries. HCC is highly refractory to cytotoxic chemotherapy. This resistance is partly related to its tumor biology, pharmacokinetic properties, and both intrinsic and acquired drug resistance. There is no convincing evidence thus far that systemic chemotherapy improves overall survival in advanced HCC patients. Other systemic approaches, such as hormonal therapy and immunotherapy, have also disappointing results. Recently, encouraging results have been shown in using sorafenib in the treatment of advanced HCC patients. In this review, we concisely summarize the evolution of developments in the systemic therapy of advanced HCC.
摘要
肝细胞癌（HCC）常见于乙型肝炎流行地区，尤其是亚洲国家。HCC对细胞毒性化疗具有高度耐药性。这种耐药性部分与其肿瘤生物学、药代动力学特性以及内在和获得性耐药有关。迄今为止，尚无令人信服的证据表明全身化疗能提高晚期HCC患者的总生存率。其他全身治疗方法，如激素治疗和免疫治疗，也取得了令人失望的结果。最近，在使用索拉非尼治疗晚期HCC患者方面已显示出令人鼓舞的结果。在本综述中，我们简要总结了晚期HCC全身治疗的发展历程。
相似文献
1
Evolution of systemic therapy of advanced hepatocellular carcinoma.
World J Gastroenterol. 2008 Nov 14;14(42):6437-41. doi: 10.3748/wjg.14.6437.
2
Sorafenib in hepatocellular carcinoma.
Br J Hosp Med (Lond). 2010 Aug;71(8):451-6. doi: 10.12968/hmed.2010.71.8.77669.
3
Advanced hepatocellular carcinoma. Review of targeted molecular drugs.
Ann Hepatol. 2011 Jan-Mar;10(1):21-7.
4
Target therapy for hepatocellular carcinoma: is sorafenib for everybody?
J Clin Gastroenterol. 2009 May-Jun;43(5):389-90. doi: 10.1097/MCG.0b013e31819eb9a6.
5
Management of hepatocellular carcinoma: beyond sorafenib.
Curr Oncol Rep. 2012 Jun;14(3):257-66. doi: 10.1007/s11912-012-0233-0.
6
Phase 2 open-label study of single-agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B-endemic Asian population: presence of lung metastasis predicts poor response.
Cancer. 2009 Jan 15;115(2):428-36. doi: 10.1002/cncr.24029.
7
[Treatment of advanced hepatocellular carcinoma].
Gastroenterol Hepatol. 2010 Jun-Jul;33(6):461-8. doi: 10.1016/j.gastrohep.2009.12.006. Epub 2010 Mar 15.
8
Sorafenib for liver cancer: the horizon broadens.
Lancet Oncol. 2009 Jan;10(1):4-5. doi: 10.1016/S1470-2045(08)70317-6.
9
Molecular targeted therapy of advanced hepatocellular carcinoma beyond sorafenib.
Expert Opin Pharmacother. 2010 Sep;11(13):2187-98. doi: 10.1517/14656561003724705.
10
New pharmacological developments in the treatment of hepatocellular cancer.
Drugs. 2009;69(18):2533-40. doi: 10.2165/11530870-000000000-00000.
引用本文的文献
1
Plectin-mediated cytoskeletal crosstalk as a target for inhibition of hepatocellular carcinoma growth and metastasis.
Elife. 2025 Mar 7;13:RP102205. doi: 10.7554/eLife.102205.
2
A review of the literature on the use of CRISPR/Cas9 gene therapy to treat hepatocellular carcinoma.
Oncol Res. 2024 Feb 6;32(3):439-461. doi: 10.32604/or.2023.044473. eCollection 2024.
3
Remodeling Serine Synthesis and Metabolism via Nanoparticles (NPs)-Mediated CFL1 Silencing to Enhance the Sensitivity of Hepatocellular Carcinoma to Sorafenib.
Adv Sci (Weinh). 2023 Jul;10(19):e2207118. doi: 10.1002/advs.202207118. Epub 2023 May 18.
4
Cisplatin or Doxorubicin Reduces Cell Viability via the PTPIVA3-JAK2-STAT3 Cascade in Hepatocellular Carcinoma.
J Hepatocell Carcinoma. 2023 Jan 30;10:123-138. doi: 10.2147/JHC.S385238. eCollection 2023.
5
LXRα activation and Raf inhibition trigger lethal lipotoxicity in liver cancer.
Nat Cancer. 2021 Feb;2(2):201-217. doi: 10.1038/s43018-020-00168-3. Epub 2021 Feb 15.
6
Enrichment and identification of differentially expressed genes in hepatocellular carcinoma stem-like cells.
Oncol Lett. 2020 Dec;20(6):299. doi: 10.3892/ol.2020.12162. Epub 2020 Sep 28.
7
Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma.
Cochrane Database Syst Rev. 2020 Jan 24;1(1):CD011313. doi: 10.1002/14651858.CD011313.pub3.
8
Trefoil factor 3 mediation of oncogenicity and chemoresistance in hepatocellular carcinoma is AKT-BCL-2 dependent.
Oncotarget. 2017 Jun 13;8(24):39323-39344. doi: 10.18632/oncotarget.16950.
9
External beam radiotherapy for unresectable hepatocellular carcinoma.
Cochrane Database Syst Rev. 2017 Mar 7;3(3):CD011314. doi: 10.1002/14651858.CD011314.pub2.
10
Target-specific delivery of siRNA into hepatoma cells' cytoplasm by bifunctional carrier peptide.
Drug Deliv Transl Res. 2017 Feb;7(1):147-155. doi: 10.1007/s13346-016-0348-1.
本文引用的文献
1
Sorafenib in advanced hepatocellular carcinoma.
N Engl J Med. 2008 Jul 24;359(4):378-90. doi: 10.1056/NEJMoa0708857.
2
Design and endpoints of clinical trials in hepatocellular carcinoma.
J Natl Cancer Inst. 2008 May 21;100(10):698-711. doi: 10.1093/jnci/djn134. Epub 2008 May 13.
3
Somatostatin receptor in human hepatocellular carcinomas: biological, patient and tumor characteristics.
Dig Surg. 2008;25(1):21-6. doi: 10.1159/000117819. Epub 2008 Feb 21.
4
Growth factor receptors and related signalling pathways as targets for novel treatment strategies of hepatocellular cancer.
World J Gastroenterol. 2008 Jan 7;14(1):1-14. doi: 10.3748/wjg.14.1.
5
Efficacy and tolerability of low-dose thalidomide as first-line systemic treatment of patients with advanced hepatocellular carcinoma.
Oncology. 2007;72 Suppl 1:67-71. doi: 10.1159/000111709. Epub 2007 Dec 13.
6
Multicentre phase II trial of capecitabine plus oxaliplatin (XELOX) in patients with advanced hepatocellular carcinoma: FFCD 03-03 trial.
Br J Cancer. 2007 Oct 8;97(7):862-7. doi: 10.1038/sj.bjc.6603956. Epub 2007 Sep 18.
7
Phase III randomized controlled trial comparing the survival of patients with unresectable hepatocellular carcinoma treated with nolatrexed or doxorubicin.
J Clin Oncol. 2007 Jul 20;25(21):3069-75. doi: 10.1200/JCO.2006.08.4046.
8
TP53 mutations and hepatocellular carcinoma: insights into the etiology and pathogenesis of liver cancer.
Oncogene. 2007 Apr 2;26(15):2166-76. doi: 10.1038/sj.onc.1210279.
9
Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC): results of a phase II study.
Cancer. 2007 Apr 1;109(7):1384-90. doi: 10.1002/cncr.22532.
10
Survival and apoptosis: a dysregulated balance in liver cancer.
Liver Int. 2007 Mar;27(2):155-62. doi: 10.1111/j.1478-3231.2006.01409.x.
Zotero 插件